EA199900057A1 - MATRIX METALLOPROTEINASE INHIBITORS - Google Patents
MATRIX METALLOPROTEINASE INHIBITORSInfo
- Publication number
- EA199900057A1 EA199900057A1 EA199900057A EA199900057A EA199900057A1 EA 199900057 A1 EA199900057 A1 EA 199900057A1 EA 199900057 A EA199900057 A EA 199900057A EA 199900057 A EA199900057 A EA 199900057A EA 199900057 A1 EA199900057 A1 EA 199900057A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mmp
- tnf
- alpha
- matrix metalloproteinase
- metalloproteinase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Производные сукцинамида формулы (I), в которых W обозначает группу -COH или -CONHOH, каждый R, Rи Rобозначает водород или органический остаток, Rобозначает остаток альфа-аминокислоты и Rобозначает органическую группу, являются ингибиторами матриксных металлопротеиназ (ММР) и высвобождения из клеток фактора-альфа некроза опухолей (TNF), поэтому их можно эффективно использовать для профилактики и лечения болезней, вызываемых ММР или TNF. Данное изобретение относится также к способу получения указанных соединений и к содержащим их фармацевтическим композициям.Международная заявка была опубликована вместе с отчетом о международном поиске.The succinamide derivatives of formula (I) in which W stands for the group —COH or —CONHOH, each R, R and R represents hydrogen or organic residue, R represents an alpha-amino acid residue and R denotes an organic group, are inhibitors of matrix metalloproteinases (MMP) and release from factor -alpha necrosis of tumors (TNF), so they can be effectively used for the prevention and treatment of diseases caused by MMP or TNF. The invention also relates to a method for producing said compounds and pharmaceutical compositions containing them. The international application was published together with an international search report.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9613547.0A GB9613547D0 (en) | 1996-06-27 | 1996-06-27 | Matrix metalloproteinase inhibitors |
PCT/EP1997/003251 WO1997049674A1 (en) | 1996-06-27 | 1997-06-20 | Matrix metalloproteinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EA199900057A1 true EA199900057A1 (en) | 1999-06-24 |
EA001432B1 EA001432B1 (en) | 2001-02-26 |
Family
ID=10796022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA199900057A EA001432B1 (en) | 1996-06-27 | 1997-06-20 | Matrix metalloproteinase inhibitors |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0920414A1 (en) |
JP (1) | JP2000514043A (en) |
KR (1) | KR20000022534A (en) |
AR (1) | AR008621A1 (en) |
AU (1) | AU733938B2 (en) |
BR (1) | BR9709902A (en) |
CA (1) | CA2257404A1 (en) |
CZ (1) | CZ430398A3 (en) |
EA (1) | EA001432B1 (en) |
GB (1) | GB9613547D0 (en) |
ID (1) | ID17792A (en) |
IL (1) | IL127262A0 (en) |
NO (1) | NO986049L (en) |
NZ (1) | NZ333550A (en) |
PL (1) | PL330897A1 (en) |
TW (1) | TW460441B (en) |
WO (1) | WO1997049674A1 (en) |
ZA (1) | ZA975631B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19719817A1 (en) * | 1997-05-13 | 1998-11-19 | Hoechst Ag | Substituted 6- and 7-aminotetrahydroisoquinoline carboxylic acids |
KR100352316B1 (en) | 1997-07-31 | 2002-09-12 | 더 프록터 앤드 갬블 캄파니 | Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors |
GB9803005D0 (en) * | 1998-02-12 | 1998-04-08 | British Biotech Pharm | Anti-inflammatory agents |
GB9804777D0 (en) * | 1998-03-07 | 1998-04-29 | British Biotech Pharm | Anti-inflammatory agents |
US6335324B1 (en) | 1998-06-25 | 2002-01-01 | Bristol-Myers Squibb Co. | Beta lactam compounds and their use as inhibitors of tryptase |
GB9901863D0 (en) | 1999-01-29 | 1999-03-17 | British Biotech Pharm | Antibacterial agents |
KR20010102486A (en) | 1999-03-03 | 2001-11-15 | 데이비드 엠 모이어 | Alkenyl- and alkynyl-containing metalloprotease inhibitors |
AU2268401A (en) * | 1999-12-17 | 2001-06-25 | Versicor Inc | Novel succinate compounds, compositions and methods of use and preparation |
GB9930754D0 (en) * | 1999-12-29 | 2000-02-16 | Smithkline Beecham Plc | Novel compounds |
AU2001271068A1 (en) * | 2000-07-18 | 2002-01-30 | Chugai Seiyaku Kabushiki Kaisha | Matrix metalloprotease inhibitors |
JP4314340B2 (en) | 2001-06-15 | 2009-08-12 | ヴィキュロン ファーマシューティカルズ インコーポレイテッド | Pyrrolidine bicyclic compound |
AR036053A1 (en) | 2001-06-15 | 2004-08-04 | Versicor Inc | N-FORMIL-HYDROXYLAMINE COMPOUNDS, A PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS |
US20110230479A1 (en) * | 2005-04-15 | 2011-09-22 | Longo Frank M | Neurotrophin mimetics and uses thereof |
KR20060116552A (en) * | 2005-05-10 | 2006-11-15 | 연세대학교 산학협력단 | N-formyl hydroxylamine derivatives as matrix metalloproteinase inhibitors |
FR2949463B1 (en) * | 2009-08-26 | 2011-09-16 | Commissariat Energie Atomique | MMP INHIBITORS |
JP5863663B2 (en) | 2009-11-12 | 2016-02-16 | ファーマトロフィックス, インコーポレイテッド | Crystal forms of neurotrophin mimetic compounds and their salts |
US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599361A (en) * | 1985-09-10 | 1986-07-08 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
DK77487A (en) * | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | hydroxylamine |
JPH05503720A (en) * | 1990-12-03 | 1993-06-17 | セルテック リミテッド | Peptidyl derivative |
CA2058797A1 (en) * | 1991-02-01 | 1992-08-02 | Michael John Broadhurst | Amino acid derivatives |
EP0520573A1 (en) * | 1991-06-27 | 1992-12-30 | Glaxo Inc. | Cyclic imide derivatives |
-
1996
- 1996-06-27 GB GBGB9613547.0A patent/GB9613547D0/en active Pending
-
1997
- 1997-06-18 TW TW086108613A patent/TW460441B/en active
- 1997-06-20 KR KR1019980710980A patent/KR20000022534A/en not_active Application Discontinuation
- 1997-06-20 EA EA199900057A patent/EA001432B1/en not_active IP Right Cessation
- 1997-06-20 AU AU33422/97A patent/AU733938B2/en not_active Ceased
- 1997-06-20 EP EP97929242A patent/EP0920414A1/en not_active Withdrawn
- 1997-06-20 BR BR9709902A patent/BR9709902A/en unknown
- 1997-06-20 NZ NZ333550A patent/NZ333550A/en unknown
- 1997-06-20 PL PL97330897A patent/PL330897A1/en unknown
- 1997-06-20 CZ CZ984303A patent/CZ430398A3/en unknown
- 1997-06-20 WO PCT/EP1997/003251 patent/WO1997049674A1/en not_active Application Discontinuation
- 1997-06-20 JP JP10502322A patent/JP2000514043A/en active Pending
- 1997-06-20 CA CA002257404A patent/CA2257404A1/en not_active Abandoned
- 1997-06-20 IL IL12726297A patent/IL127262A0/en unknown
- 1997-06-25 ZA ZA9705631A patent/ZA975631B/en unknown
- 1997-06-26 AR ARP970102813A patent/AR008621A1/en unknown
- 1997-06-26 ID IDP972218A patent/ID17792A/en unknown
-
1998
- 1998-12-22 NO NO986049A patent/NO986049L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU3342297A (en) | 1998-01-14 |
IL127262A0 (en) | 1999-09-22 |
NZ333550A (en) | 2000-07-28 |
ID17792A (en) | 1998-01-29 |
JP2000514043A (en) | 2000-10-24 |
BR9709902A (en) | 1999-08-10 |
PL330897A1 (en) | 1999-06-07 |
CA2257404A1 (en) | 1997-12-31 |
AR008621A1 (en) | 2000-02-09 |
GB9613547D0 (en) | 1996-08-28 |
EP0920414A1 (en) | 1999-06-09 |
AU733938B2 (en) | 2001-05-31 |
EA001432B1 (en) | 2001-02-26 |
NO986049D0 (en) | 1998-12-22 |
KR20000022534A (en) | 2000-04-25 |
CZ430398A3 (en) | 1999-08-11 |
ZA975631B (en) | 1998-01-30 |
TW460441B (en) | 2001-10-21 |
NO986049L (en) | 1999-03-01 |
WO1997049674A1 (en) | 1997-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA199900057A1 (en) | MATRIX METALLOPROTEINASE INHIBITORS | |
EA200101085A1 (en) | HYDROXAMIC ACIDS, DERIVATIVES OF AROMATIC SULPHONES, - METALLOPROTEASIS INHIBITORS | |
BR9810841A (en) | Alicyclic metalloprotease inhibitors | |
DOP2004001052A (en) | 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1 INHIBITORS AMINO | |
EA200000871A1 (en) | PHOSPHOLIPASE ENZYME INHIBITORS | |
EA200400480A1 (en) | N-SUBSTITUTED PYRROLIDINE DERIVATIVES AS DIPEPTIDYLPEPIDASE INHIBITORS | |
EA200100804A1 (en) | SULPHOOROMATIC DERIVATIVES OF HYDROXAMIC ACID AS METHYPE PROTEASIS INHIBITORS | |
BR9509212A (en) | Compound pharmaceutical composition method of inhibiting prostaglandin H synthase in a mammal method of treating an inflammatory disease in a mammal and method of treating pyresis in a mammal | |
DK0927161T3 (en) | Substituted cyclic amine metalloprotease inhibitors | |
EA200301216A1 (en) | MULTICYCLIC HETEROARYLS SUBSTITUTED WITH QUINUCLIDINES FOR THE DISEASE TREATMENT | |
NO963499L (en) | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof | |
BR9909620A (en) | Substituted pyrrolidine hydroxamate metalloprotease inhibitors | |
EA200100971A1 (en) | NEW COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | |
BR9713186A (en) | 1,3-diheterocyclic metalloprotease inhibitors | |
ES2185307T3 (en) | FARNESIL TRANSFERASA INHIBITORS THAT HAVE A PIPERIDINIC STRUCTURE AND PROCEDURE FOR THEIR PREPARATION. | |
NO20024521L (en) | Heterocyclic side chain-containing metalloprotease inhibitors | |
BR9713178A (en) | Spirocyclic metalloprotease inhibitors. | |
NO991674D0 (en) | Interleukin-1 <beta> converting enzyme inhibitor sulfonamides | |
EA200201223A1 (en) | TIENODIBENZOESULENE COMPOUNDS AS AN INHIBITORS OF TUMOR NECROSIS FACTOR | |
BR9712792A (en) | Bidentate metalloprotease inhibitors. | |
EA200400708A1 (en) | INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1 | |
TR200003252T2 (en) | Interleukin-1ß converting enzyme succinamide inhibitors. | |
BR0109328A (en) | Unsubstituted metalloprotease inhibitors containing heterocyclic side chain | |
DE69702182T2 (en) | ALKYLATED STYROLE AS PRODRUGS TO COX-2 INHIBITORS | |
BR0109348A (en) | Unsubstituted metalloprotease inhibitors which contain carbocyclic side chains |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |